diaDexus gets US patent for heart disease test:
This article was originally published in Clinica
Executive Summary
diaDexus has been issued with a US patent covering its blood test for a patient's susceptibility to atherosclerosis. The immunoassay-based test measures the levels of Lp-PLA2, a risk factor for coronary heart disease (see Clinica No 931, p 19). The Santa Clara, California company says that Lp-PLA2 is independent of other known risk factors, including low-density lipoprotein cholesterol and C-reactive protein. The patent was licensed from GlaxoSmithKline, which discovered that Lp-PLA2 was associated with atherosclerotic plaque.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.